NICE | August 2018 | Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089]
The Department of Health and Social Care has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using lenvatinib in the NHS in England. The appraisal committee has considered the evidence submitted by the company and the views of non-company consultees and commentators, clinical experts and patient experts.
The Consultation Appraisal document has been prepared for consultation; It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from the consultees and commentators for this appraisal and the public. This document should be read along with the evidence.
The appraisal committee is interested in receiving comments on the following:
Has all of the relevant evidence been taken into account?
Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
Are the recommendations sound and a suitable basis for guidance to the NHS?
Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity? (Source: NICE)
The key dates for this appraisal are:
Closing date for comments: 30 August 2018
Second appraisal committee meeting: 27 September 2018